-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Virios Therapeutics Announces Publication Of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID
Virios Therapeutics Announces Publication Of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –
- Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation -
- Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms –
ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced that the World Intellectual Property Organization (WIPO) has published Virios' global patent application titled "Valacyclovir and Celecoxib for the Treatment of Alzheimer's and COVID-19", which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety. Combination treatment with valacyclovir and celecoxib is presently being assessed in a double blind, placebo-controlled study under the direction of Dr. Lucinda Bateman, MD, supported by an unrestricted, investigational grant provided by the Company to the Bateman Horne Center. Results from this important trial are expected this summer.
The 2024 National Center for Health Statistics Household Pulse Survey estimates that 17.6% of the US population have experienced LC, representing upwards of 45 million potential adult patients, since the pandemic started in November of 2019. Previous estimates suggest that up to 10 million children in the US have also experienced LC. There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.
A multitude of studies suggest that while LC is a consequence of SARS-CoV-2 virus infection, the development of LC seems related to immune system dysfunction and complement activation. It has been postulated that an exhausted immune response to COVID-19 enables reactivation of previously dormant herpesviruses. Reactivated herpesviruses such as Epstein-Barr virus (EBV) may be associated with fatigue and cognitive dysfunction. Fatigue and cognitive dysfunction are predominant LC symptoms.
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally –
-新專利將擴大Virios全球抗病毒產品線的覆蓋範圍並擴大其潛在價值—
- Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation -
-活躍的長冠狀病毒以免疫功能障礙導致皰疹病毒複發性重新激活爲特徵-
- Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms –
-公佈的數據顯示,長期 COVID 患者的愛潑斯坦-巴爾皰疹病毒增多,凸顯了抗病毒療法治療疲勞和其他長期 COVID 症狀的潛力 —
ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced that the World Intellectual Property Organization (WIPO) has published Virios' global patent application titled "Valacyclovir and Celecoxib for the Treatment of Alzheimer's and COVID-19", which covers the use of IMC-2, a proprietary combination of valacyclovir and celecoxib. This milestone enables Virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
亞特蘭大,2024年3月26日(GLOBE NEWSWIRE)——Virios Therapeutics, Inc.(納斯達克股票代碼:VIRI)(“公司”)是一家處於開發階段的生物技術公司,專注於推進治療包括纖維肌痛(“FM”)和長冠狀病毒(“LC”)在內的新型抗病毒療法,今天宣佈,世界知識產權組織(WIPO)已經公佈了Virios的全球專利申請標題爲 “伐昔洛韋和塞來昔布用於治療阿爾茨海默氏症和COVID-19”,其中涵蓋了 IMC-2 的使用,這是伐昔洛韋的專有組合塞來昔布。這一里程碑使Virios能夠簡化在全球範圍內獲得專利保護的流程,這是全球目標國家進入國家專利審查階段的先導。
An open-label, exploratory LC study sponsored by Virios demonstrated that treatment with the combination of valacyclovir and celecoxib resulted in clinical and statistically significant reductions in LC associated fatigue, orthostatic intolerance, pain and anxiety. Combination treatment with valacyclovir and celecoxib is presently being assessed in a double blind, placebo-controlled study under the direction of Dr. Lucinda Bateman, MD, supported by an unrestricted, investigational grant provided by the Company to the Bateman Horne Center. Results from this important trial are expected this summer.
由Virios贊助的一項開放標籤的探索性LC研究表明,伐昔洛韋和塞來昔布聯合治療可顯著減輕LC相關的疲勞、體位不耐受、疼痛和焦慮。在醫學博士露辛達·貝特曼博士的指導下,一項雙盲、安慰劑對照的研究目前正在評估伐昔洛韋和塞來昔布的聯合治療,該研究得到了該公司向貝特曼·霍恩中心提供的不受限制的研究補助金的支持。這項重要試驗的結果預計將於今年夏天公佈。
The 2024 National Center for Health Statistics Household Pulse Survey estimates that 17.6% of the US population have experienced LC, representing upwards of 45 million potential adult patients, since the pandemic started in November of 2019. Previous estimates suggest that up to 10 million children in the US have also experienced LC. There are no treatments approved by the FDA to treat the symptoms associated with LC, further highlighting the need for new treatments.
2024年國家衛生統計中心家庭脈搏調查估計,自2019年11月疫情爆發以來,有17.6%的美國人口經歷過LC,這意味着超過4,500萬潛在的成年患者。先前的估計表明,美國有多達1000萬兒童也經歷過LC。美國食品藥品管理局批准沒有任何治療方法可以治療與LC相關的症狀,這進一步凸顯了對新療法的需求。
A multitude of studies suggest that while LC is a consequence of SARS-CoV-2 virus infection, the development of LC seems related to immune system dysfunction and complement activation. It has been postulated that an exhausted immune response to COVID-19 enables reactivation of previously dormant herpesviruses. Reactivated herpesviruses such as Epstein-Barr virus (EBV) may be associated with fatigue and cognitive dysfunction. Fatigue and cognitive dysfunction are predominant LC symptoms.
大量研究表明,雖然LC是SARS-CoV-2病毒感染的結果,但LC的發展似乎與免疫系統功能障礙和補體激活有關。據推測,對 COVID-19 的免疫反應耗盡可以重新激活以前處於休眠狀態的皰疹病毒。重新激活的皰疹病毒,例如愛潑斯坦-巴爾病毒(EBV)可能與疲勞和認知功能障礙有關。疲勞和認知功能障礙是主要的 LC 症狀。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧